ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: "Of insurance plans that cover fertility treatments, many continue to define infertility as the inability to conceive after 6 to 12 months of unprotected heterosexual intercourse." The Perspective is titled "Who Counts as Infertile? A Missed Opportunity for Inclusion” and the author is Paula Amato, M.D., and I. Glenn Cohen, J.D. The background color is purple and includes the NEJM identity.

ALT A quote from an NEJM Voices blog post reads as follows: “Every visit can hide a treasure waiting just beneath the surface. I don’t always find it, because I’m not always in a state of mind to look. But when I do, I’m reminded yet again what a gift it is to be let into someone’s life, even just for 15 minutes.” The author is Michelle Kittleson, M.D. The background is a red-orange gradient and includes the NEJM Voices logo.

ALT Four figures showing the trial design for cohort 2, DENV-3 RNA viral loads, and mosnodenvir plasma concentrations. Panel A shows the trial design for Cohort 2. Twice-daily loading doses (LDs) were administered for 2 days, starting on day −2, and the maintenance doses (MDs) were administered for 21 days, starting on day 1. Panel B shows the DENV-3 viral load, assessed as the log10 area under the concentration–time curve (AUC) from day 1 through day 29. Panels C and D show the mosnodenvir plasma concentrations over time (through day 85 in Panel C and through day 29 in Panel D) in the pharmacokinetic analysis.

ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: "Without targeted, age-appropriate screening tools, needs will be misidentified, resources will be used inefficiently, and opportunities to improve people’s health and well-being will be missed.” The Perspective is titled " Health-Related Social Needs among Older Adults — Addressing Mismeasurement” and the authors are Mark A. Unruh, Ph.D., and Joshua R. Vest, Ph.D., M.P.H. The background color is dark orange and includes the NEJM identity.

ALT This image contains an excerpt from the Research Summary "Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis” published in the New England Journal of Medicine. It details participant demographics: 252 adults; mean age, 42 years (men: 58%; women: 42%). To the right, there is an illustration of a patient with ulcerative colitis. Below are boxes and tablets for the three tested icotrokinra doses (400 mg, 200 mg, and 100 mg) and placebo. A prompt to read the full Research Summary at NEJM.org sits at the bottom.

ALT Four medical images from the Images in Clinical Medicine article "Alkaptonuria.” Panel A: A photo of patches of darkly pigmented sclera. Panel B: A radiograph of the lumbosacral spine showing narrowing of the intervertebral disk space, disk-space calcification, and vertebral end-plate sclerosis (lateral view). Panel C: A radiograph of the pelvis showing destruction of the femoral heads (anterior view). Panel D: A photo of a urine sample that turned black after being left out overnight at room temperature.

ALT Three photos from the Morning Report titled "An 18-Year-Old Woman with Abdominal Pain" show the darkening of urine after exposure to light and ambient air. Panel A: The urine sample, which was initially clear and yellow, became progressively darker after 6 hours of exposure to light and ambient air. Panel B: The sample after 24 hours. Panel C: The sample after 48 hours.

ALT Quote about digital health management: "These findings show that managing digital health transformations requires more than just launching an online platform; it requires focus on continuous workflow reengineering." Citation: Supplemental Issue: Impact of E-visits on Outpatient Volume and Service Time: Evidence from a Large Public Hospital in China' by X. Xu et al. The NEJM Catalyst Innovations in Care Delivery logo is at bottom left.

ALT A quote from an NEJM Voices blog post reads as follows: “Even as we make progress in cancer treatments, every breakthrough allows us to ask even more questions. Trials are the way we move forward and offering patients the opportunity to participate in them is critical.” The author is Don Dizon, M.D. The background color is red and includes the NEJM Voices logo.

ALT Two forest plots showing the primary and key secondary end points. Panel A shows the participants with an HIV viral load of less than 50 copies per milliliter at week 48 (primary end point). Panel B shows the participants with virologic nonresponse and those with confirmed virologic failure (key secondary end points).

ALT A patient lies in a hospital bed connected to a dialysis machine by several red tubes. The text "Intermittent Hemodialysis vs. Continuous RRT” is written above the illustration.

ALT An image from a NEJM Voices article by Paul E. Sax, M.D., features the words "THANK YOU" in bold, colorful letters against a pink background.

ALT A bullet list of key points from the Clinical Practice article “Adult Attention Deficit–Hyperactivity Disorder” on a yellow background. The New England Journal of Medicine identity sits at the bottom.

ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: " Many physiological changes that become more common in older age, such as visual and hearing impairment, neuropathy, and cognitive decline, may affect a person’s ability to safely operate a firearm.” The Perspective is titled "Firearm-Related Discussions as an Age-Friendly Intervention” and the authors are Lena K. Makaroun, M.D., Timothy W. Farrell, M.D., and Marian E. Betz, M.D., M.P.H. The text is displayed on a simple white background with a yellowish-olive green border. The NEJM identity sits at the bottom.

ALT Four bar graphs showing the percentages of participants with a clinical response at week 12 (Panel A, primary end point) and the percentages of participants with clinical remission (Panel B), symptomatic remission (Panel C), and endoscopic improvement (Panel D) at week 12 (secondary end points).

ALT A visual representation of the IMPALA trial, which evaluated whether a longer-acting injectable therapy could maintain viral suppression in adults with human immunodeficiency virus who have adherence challenges to daily antiretroviral therapy.

ALT A quote from a Perspective published in the New England Journal of Medicine reads as follows: "I had lost my own pocket medical expert that I so cherished. We had learned so much together, we had made informed decisions together, we had improved my patients’ care together. And now it was gone.” The Perspective is titled “Not Available in Your Country” and the author is Christos P. Kotanidis, M.D., D.Phil. The background color is orange and includes the NEJM logo.

ALT This image contains an excerpt from the Research Summary "In Vivo CRISPR Gene Editing in Hereditary Angioedema” published in the New England Journal of Medicine. It shows a comparison between Lonvo-z and Placebo. An illustration depicts an individual experiencing swelling from hereditary angioedema. The study includes 80 adults with a median age of 42 (women: 69%; men: 31%). A prompt to read the full Research Summary at NEJM.org sits at the bottom.